BTG to receive $7M PH III trial milestone from Tolerx
The UK's BTG life sciences company is to receive a $7.5 million milestone payment from Tolerx, triggered by the initiation of a pivotal Phase III trial of TRX4 (otelixizumab).
The DEFEND trial will evaluate TRX4 in the treatment of 240 people aged 18 to 35 with new onset type 1 diabetes, dosed no more than 90 days after diagnosis. The primary endpoint will be the inhibition of the destruction of pancreatic beta cells, reducing the necessary amount of insulin required to regulate blood glucose levels, as measured by C-peptide levels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze